A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine

Shin Komiyama, Masaru Nakamura, Isao Murakami, Yoshiko Kuwabara, Takashi Kurahashi, Kyoko Tanaka, Mikio Mikami

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis. No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer. We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis. Case report: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary. She had recurrent tumors after primary cytoreductive surgery, which were unresectable and also resistant to paclitaxel, carboplatin, irinotecan, and oral etoposide. After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease. The toxicity of this drug was in the acceptable range. Conclusion: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary. It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.

Original languageEnglish
Pages (from-to)565-568
Number of pages4
JournalArchives of Gynecology and Obstetrics
Volume278
Issue number6
DOIs
Publication statusPublished - 2008 Dec
Externally publishedYes

Fingerprint

gemcitabine
Clear Cell Adenocarcinoma
Salvage Therapy
Peritonitis
Ovary
irinotecan
Neoplasms
Pharmaceutical Preparations
Drug Therapy
Taxoids
Liver
Carboplatin
Etoposide
Paclitaxel
Platinum
Drug-Related Side Effects and Adverse Reactions
Ascites

Keywords

  • Carcinomatous peritonitis
  • Gemcitabine
  • Irinotecan
  • Recurrent clear cell adenocarcinoma of the ovary
  • Salvage therapy
  • Stabilization

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. / Komiyama, Shin; Nakamura, Masaru; Murakami, Isao; Kuwabara, Yoshiko; Kurahashi, Takashi; Tanaka, Kyoko; Mikami, Mikio.

In: Archives of Gynecology and Obstetrics, Vol. 278, No. 6, 12.2008, p. 565-568.

Research output: Contribution to journalArticle

@article{04fbfc0f51e6432f92bd8db07461c897,
title = "A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine",
abstract = "Introduction: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis. No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer. We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis. Case report: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary. She had recurrent tumors after primary cytoreductive surgery, which were unresectable and also resistant to paclitaxel, carboplatin, irinotecan, and oral etoposide. After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease. The toxicity of this drug was in the acceptable range. Conclusion: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary. It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.",
keywords = "Carcinomatous peritonitis, Gemcitabine, Irinotecan, Recurrent clear cell adenocarcinoma of the ovary, Salvage therapy, Stabilization",
author = "Shin Komiyama and Masaru Nakamura and Isao Murakami and Yoshiko Kuwabara and Takashi Kurahashi and Kyoko Tanaka and Mikio Mikami",
year = "2008",
month = "12",
doi = "10.1007/s00404-007-0396-3",
language = "English",
volume = "278",
pages = "565--568",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine

AU - Komiyama, Shin

AU - Nakamura, Masaru

AU - Murakami, Isao

AU - Kuwabara, Yoshiko

AU - Kurahashi, Takashi

AU - Tanaka, Kyoko

AU - Mikami, Mikio

PY - 2008/12

Y1 - 2008/12

N2 - Introduction: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis. No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer. We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis. Case report: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary. She had recurrent tumors after primary cytoreductive surgery, which were unresectable and also resistant to paclitaxel, carboplatin, irinotecan, and oral etoposide. After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease. The toxicity of this drug was in the acceptable range. Conclusion: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary. It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.

AB - Introduction: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis. No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer. We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis. Case report: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary. She had recurrent tumors after primary cytoreductive surgery, which were unresectable and also resistant to paclitaxel, carboplatin, irinotecan, and oral etoposide. After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease. The toxicity of this drug was in the acceptable range. Conclusion: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary. It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.

KW - Carcinomatous peritonitis

KW - Gemcitabine

KW - Irinotecan

KW - Recurrent clear cell adenocarcinoma of the ovary

KW - Salvage therapy

KW - Stabilization

UR - http://www.scopus.com/inward/record.url?scp=54349089858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349089858&partnerID=8YFLogxK

U2 - 10.1007/s00404-007-0396-3

DO - 10.1007/s00404-007-0396-3

M3 - Article

VL - 278

SP - 565

EP - 568

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 6

ER -